Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any gender.
• People with a life expectancy of more than 12 weeks.
• People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard cancer performance scale (scores 0 to 2 on the ECOG scale — confirm with trial site if unsure what this means).
• People who have been diagnosed with active multiple myeloma (MM), confirmed using international diagnostic guidelines.
• People who have either had a stem cell transplant (SCT) or have been assessed as not suitable for one.
• People who have previously been treated with at least three specific types of myeloma therapy — an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 treatment — and whose disease is either no longer responding to, or who could not tolerate, current standard treatments.
• People whose myeloma is measurable according to international myeloma guidelines.
• People whose heart, liver, kidneys, and other organ systems are functioning at a level defined in the study protocol (confirm specific thresholds with trial site).

Who may not be able to join:

• People entering the Phase 2a part of the trial who have previously received any treatment — approved or experimental — that targets a protein called BCMA.
• People whose myeloma has spread to the brain or spinal cord.
• People with a condition called plasma cell leukemia (a rare and aggressive form of myeloma found in the blood).
• People with a history of congestive heart failure.
• People who have had a stem cell transplant (either using their own or a donor's cells) within the 12 weeks before the first treatment, or who are planning to have their own stem cell transplant.
• People who have had significant complications (graft versus host disease) following a donor stem cell transplant within the 12 months before starting the study treatment.
• People who have had radiotherapy within 21 days before the first study treatment.
• People with a history of any other cancer that is known to still be active.
• People with a known HIV infection.
• People who have an active infection currently being treated with antibiotics, antivirals, or other anti-infective medicines.
• People who test positive for hepatitis B surface antigen or hepatitis B core antigen.
• People who test positive for hepatitis C virus.
• People with a currently active liver or bile duct disease.

Important: Always verify eligibility with the trial site directly before applying.